Citius Oncology, Inc.

What they do

Citius Oncology develops and commercializes targeted oncology therapies, with LYMPHIR (denileukin diftitox-cxdl) as its only approved product. LYMPHIR treats persistent or recurrent CTCL, a rare non-Hodgkin lymphoma, and was approved by the FDA in August 2024. The company commercializes LYMPHIR in the U.S. with a small targeted sales force focused on major cancer centers and partners for ex-U.S. markets. It is majority-owned by Citius Pharmaceuticals (about 77.9% as of December 17, 2025) and operates as a standalone public company following an August 2024 merger.

Revenue drivers

• LYMPHIR U.S. product sales — Revenue commenced in December 2025 on launch and is recognized when wholesaler orders are fulfilled; first nine months of fiscal 2026 revenue was $7.1 million, with quarterly revenue of $3.9 million (Dec 2025), $1.7 million (Mar 2026) and $1.5 million (Jun 2026).
• Out-licensing and royalties outside the U.S. — The company's stated strategy is to partner for markets outside the U.S. to generate royalty income; no ex-U.S. revenue is reported in the excerpts. The Eisai license excludes Japan and certain parts of Asia, where Eisai retains rights.

Recent performance

For the fiscal third quarter ended June 30, 2026, revenue was $1.5 million, down from $3.9 million in the quarter ended December 31, 2025, though revenue is recognized on wholesaler fulfillment and can lag institutional demand. The company reported $7.1 million in revenue for the first nine months of fiscal 2026. Institutional vial orders grew 31% sequentially, from 708 in the March 2026 quarter to 926 in the June 2026 quarter, and 383 vials were ordered in July 2026, the largest month to date. Since launch, 44 institutions have ordered LYMPHIR, and new ordering institutions rose 80% sequentially in the June 2026 quarter. The company reported near-universal payer coverage with no reimbursement denials or prior authorization barriers reported to date.

Strategy

Citius Oncology is focused on commercializing LYMPHIR in the U.S. with a targeted sales force aimed at major cancer centers and community infusion centers. In August 2026, the commercial and medical affairs organizations expanded to 29 people with nationwide coverage, executed with exclusive commercialization partner EVERSANA, targeting formulary inclusion at 100 priority institutions by year-end. The company is also advancing two investigator-initiated Phase 1 studies of LYMPHIR in combination settings, including with pembrolizumab in recurrent or refractory gynecologic cancers. It intends to commercialize independently in the U.S. and partner for ex-U.S. markets, and it continues to evaluate strategic alternatives. Management states it is maintaining healthy product margins while pursuing broader adoption.

Risks

• Going concern — The independent registered public accounting firm's report includes an explanatory paragraph stating substantial doubt about the company's ability to continue as a going concern.
• Need for substantial additional funding — The company has generated no operating revenue prior to LYMPHIR and will need to raise additional capital; at September 30, 2025 it estimated capital would fund operations only through March 2026, after $6.0 million raised by Citius Pharma in October 2025 and $18.0 million raised by the company in December 2025.
• Commercialization and manufacturing dependence — Future results depend on successfully launching and selling LYMPHIR, covering licensing payments, product manufacturing and third-party goods and services, and procuring cGMP commercial-scale supply.
• Nasdaq listing and related-party dependence — The company must maintain compliance with Nasdaq continued listing requirements, and an 8-K dated April 28, 2026 reported a delisting notice or listing-rule failure; it also relies on Citius Pharma for funding, shared services and as guarantor of its payment obligations to Dr. Reddy's.

Outlook

Management says institutional demand is accelerating and expects that to drive increased wholesaler orders and revenue, citing July 2026 as the largest vial order month to date. The company targets formulary inclusion at 100 priority institutions by year-end and has expanded its commercial and medical affairs teams to nationwide coverage. It also points to investigator-initiated combination studies as supporting LYMPHIR's longer-term value. Management states the positive trajectory of formulary approvals, institutional adoption and unit demand gives it confidence in a robust remainder of the fiscal year.